Biotech startups that raised Series D or later in Massachusetts, United States
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Alzheon | Framingham | Series F | $78.8M | 2026-09-10 |
| Elucid | Boston | Series D | $36.5M | 2025-10-22 |
| Variantyx | Framingham | Series D | $36.0M | 2025-04-01 |
| Insilico Medicine | Cambridge | Series E | $123.0M | 2025-03-13 |
| Inari | Cambridge | Series G | $144.0M | 2025-01-07 |
| SeLux Diagnostics | Charlestown | Series D | $48.0M | 2024-04-01 |
| Emulate | Boston | Series F | $47.1M | 2024-03-20 |
| Lyndra Therapeutics | Watertown | Series E | $101.0M | 2023-12-21 |
8 rows of the CSV in 5 of its 18 columns.
- The 40 biotech startups in Massachusetts, United States whose last round is Series D or later have raised $7.3B in total.
- 6 of them closed their most recent round in the last 12 months, $500.8M combined.
- The largest of those rounds is LifeMine Therapeutics' $188.0M Series E, dated August 2026.
- The most recent is Alzheon's $78.8M Series F on 10 September 2026.
- Deerfield is an investor in 2 of them, more than any other fund.
- Health care is the most common other sector, with 37 companies (92%).
- 0% were founded in 2020 or later; the median founding year is 2013.
- The most common team size is 11 to 50 employees (35% of companies with a recorded size).
- 2 are unicorns, valued at $1 billion or more.
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
9 of 40| Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Alzheon | Alzheon develops treatments for neurodegenerative disorders as a clinical-stage biotechnology company. | Biotech | Framingham | Series F | $78.8M | 2026-09-10 | $343.3M | Ally Bridge Group, National Institute on Aging | 11 to 50 | 2013 |
| Elucid | Elucid applies AI to medical images to support precision medicine for cardiovascular disease. | Biotech | Boston | Series D | $36.5M | 2025-10-22 | $166.2M | National Science Foundation, Sand Hill Angels, IAG Capital Partners +1 | 101 to 250 | 2013 |
| Variantyx | Variantyx offers molecular diagnostics and advanced genetic testing services. | Biotech | Framingham | Series D | $36.0M | 2025-04-01 | $136.5M | Pitango VC, Bosch Ventures, Kreos Capital +2 | 101 to 250 | 2014 |
| Insilico Medicine | Insilico Medicine develops an AI platform for drug development targeting cancer and age-related diseases. | Artificial intelligence | Cambridge | Series E | $123.0M | 2025-03-13 | $624.3M | Qiming Venture Partners, F-Prime, Warburg Pincus +1 | 101 to 250 | 2014 |
| Inari Unicorn | Inari is a seed design and biotechnology company developing seeds for a nature-positive food system. | Biotech | Cambridge | Series G | $144.0M | 2025-01-07 | $753.0M | EDBI, Alexandria Venture Investments, CPP Investments +2 | 251 to 500 | 2016 |
| Emulate | Emulate creates advanced in vitro models to study how diseases, medicines, and chemicals affect human health. | Biotech | Boston | Series F | $47.1M | 2024-03-20 | $271.3M | Alumni Ventures, Qiming Venture Partners, National Institutes of Health | 51 to 100 | 2013 |
| Lyndra Therapeutics | Lyndra Therapeutics creates oral dosage forms that release drugs over the long term. | Biotech | Watertown | Series E | $101.0M | 2023-12-21 | $284.6M | Polaris Partners, Bill & Melinda Gates Foundation, Invus | 51 to 100 | 2015 |
| Biofourmis Unicorn | Biofourmis develops healthcare technology platforms that monitor patients at home. | Artificial intelligence | Boston | Series D | $20.0M | 2022-07-27 | $463.6M | Sequoia Capital, Intel Capital, Peak XV Partners +1 | 251 to 500 | 2015 |
| Finch Therapeutics | Finch Therapeutics develops microbiome-based treatments for patients with serious unmet medical needs. | Artificial intelligence | Somerville | Series D | $90.0M | 2020-09-17 | $188.8M | Avenir, DFO Management, Willett Advisors LLC +1 | 11 to 50 | 2017 |
Table 1. Biotech startups that raised Series D or later in Massachusetts, United States: the 9 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 40.
Largest rounds
Last 12 months| # | Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Alzheon | Alzheon develops treatments for neurodegenerative disorders as a clinical-stage biotechnology company. | Biotech | Framingham | Series F | $78.8M | 2026-09-10 | $343.3M | Ally Bridge Group, National Institute on Aging | 11 to 50 | 2013 |
Table 2. Biotech startups that raised Series D or later in Massachusetts, United States: the 1 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | Deerfield | Hedge fund | New York, United States | 2 | 5% | ||
| 2 | Qiming Venture Partners | Venture capital firm | Shanghai, China | 2 | 5% | ||
| 3 | EDBI | Venture capital firm | Singapore | 2 | 5% | ||
| 4 | RA Capital Management | Startup incubator | Boston, United States | 2 | 5% | ||
| 5 | National Institutes of Health | Entrepreneurship program | Bethesda, United States | 2 | 5% | ||
| 6 | Ally Bridge Group | Private equity firm | Hong Kong | 1 | 2% | 1 | Alzheon |
| 7 | National Institute on Aging | Government investment office | Bethesda, United States | 1 | 2% | 1 | Alzheon |
| 8 | Aphelion Capital | Micro VC fund | Littleton, United States | 1 | 2% | ||
| 9 | IAG Capital Partners | Venture capital firm | Charleston, United States | 1 | 2% | ||
| 10 | Sand Hill Angels | Angel group | Mountain View, United States | 1 | 2% | ||
| 11 | National Science Foundation | Entrepreneurship program | Alexandria, United States | 1 | 2% | ||
| 12 | Pitango VC | Venture capital firm | Herzliya, Israel | 1 | 2% | ||
| 13 | Kreos Capital | Venture capital firm | London, United Kingdom | 1 | 2% | ||
| 14 | New Era Capital Partners | Venture capital firm | Tel Aviv, Israel | 1 | 2% | ||
| 15 | Bosch Ventures | Corporate venture arm | Stuttgart, Germany | 1 | 2% |
Table 3. Biotech startups that raised Series D or later in Massachusetts, United States: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 37 | 92% | $6.3B |
| Software | 6 | 15% | $1.7B |
| Artificial intelligence | 4 | 10% | $1.4B |
| Energy | 1 | 2% |
Table 4. Biotech startups that raised Series D or later in Massachusetts, United States by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Series D+ | 40 | 100% | $47.1M |
Table 5. Biotech startups that raised Series D or later in Massachusetts, United States by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Cities
| Cities | Companies | Share |
|---|---|---|
| Cambridge | 12 | 30% |
| Boston | 5 | 12% |
| Waltham | 3 | 8% |
| Framingham | 2 | 5% |
| Beverly | 2 | 5% |
| Watertown | 2 | 5% |
| Billerica | 2 | 5% |
| Somerville | 2 | 5% |
| Lexington | 2 | 5% |
| Bedford | 2 | 5% |
| Newton | 1 | 2% |
| Woburn | 1 | 2% |
Table 6. Biotech startups that raised Series D or later in Massachusetts, United States by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| September 2026 | 1 | 17% | $78.8M |
| August 2026 | 2 | 33% | $254.0M |
| April 2026 | 2 | 33% | $120.0M |
| January 2026 | 1 | 17% | $48.0M |
Table 7. Biotech startups that raised Series D or later in Massachusetts, United States: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 6 | 15% | $500.8M |
| 2025 | 6 | 15% | $364.7M |
| 2024 | 3 | 8% | $240.1M |
| 2023 | 3 | 8% | $559.8M |
| 2022 | 2 | 5% | $130.0M |
| 2021 | 3 | 8% | $196.0M |
Table 8. Biotech startups that raised Series D or later in Massachusetts, United States by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2015 to 2019 | 13 | 32% |
| 2010 to 2014 | 13 | 32% |
| Before 2010 | 14 | 35% |
Table 9. Biotech startups that raised Series D or later in Massachusetts, United States by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 2 | 5% |
| 11 to 50 | 14 | 35% |
| 51 to 100 | 12 | 30% |
| 101 to 250 | 9 | 22% |
| 251 to 500 | 3 | 8% |
Table 10. Biotech startups that raised Series D or later in Massachusetts, United States by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its most recent funding round is Series D or later and its headquarters is in Massachusetts, United States. On 16 November 2026 that is 40 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 9 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 40 rows: 0 have no round amount, 0 no city and 6 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in Massachusetts, United States whose last round is Series D or later are on the list?
- 40, in the file dated 16 November 2026. 6 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 40 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.